| Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7 P Wang, MS Nair, L Liu, S Iketani, Y Luo, Y Guo, M Wang, J Yu, B Zhang, ... Nature 593 (7857), 130-135, 2021 | 2293 | 2021 |
| Observational study of hydroxychloroquine in hospitalized patients with Covid-19 J Geleris, Y Sun, J Platt, J Zucker, M Baldwin, G Hripcsak, A Labella, ... New England Journal of Medicine 382 (25), 2411-2418, 2020 | 1908 | 2020 |
| Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 L Liu, S Iketani, Y Guo, JFW Chan, M Wang, L Liu, Y Luo, H Chu, Y Huang, ... Nature 602 (7898), 676-681, 2022 | 1210 | 2022 |
| The challenge of HIV-1 subtype diversity BS Taylor, ME Sobieszczyk, FE McCutchan, SM Hammer New England Journal of Medicine 358 (15), 1590-1602, 2008 | 1070 | 2008 |
| Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series MG Argenziano, SL Bruce, CL Slater, JR Tiao, MR Baldwin, RG Barr, ... bmj 369, 2020 | 897 | 2020 |
| Antibody evasion properties of SARS-CoV-2 Omicron sublineages S Iketani, L Liu, Y Guo, L Liu, JFW Chan, Y Huang, M Wang, Y Luo, J Yu, ... Nature 604 (7906), 553-556, 2022 | 789 | 2022 |
| Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine SM Hammer, ME Sobieszczyk, H Janes, ST Karuna, MJ Mulligan, ... New England Journal of Medicine 369 (22), 2083-2092, 2013 | 713 | 2013 |
| Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4 and BA. 5 Q Wang, Y Guo, S Iketani, MS Nair, Z Li, H Mohri, M Wang, J Yu, ... Nature 608 (7923), 603-608, 2022 | 678 | 2022 |
| Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine AR Falsey, ME Sobieszczyk, I Hirsch, S Sproule, ML Robb, L Corey, ... New England Journal of Medicine 385 (25), 2348-2360, 2021 | 638 | 2021 |
| Acute liver injury in COVID‐19: prevalence and association with clinical outcomes in a large US cohort MM Phipps, LH Barraza, ED LaSota, ME Sobieszczyk, MR Pereira, ... Hepatology 72 (3), 807-817, 2020 | 379 | 2020 |
| Gastrointestinal symptoms and coronavirus disease 2019: a case-control study from the United States YR Nobel, M Phipps, J Zucker, B Lebwohl, TC Wang, ME Sobieszczyk, ... Gastroenterology 159 (1), 373-375. e2, 2020 | 372 | 2020 |
| Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition L Corey, PB Gilbert, M Juraska, DC Montefiori, L Morris, ST Karuna, ... New England Journal of Medicine 384 (11), 1003-1014, 2021 | 364 | 2021 |
| Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study DE Freedberg, J Conigliaro, TC Wang, KJ Tracey, MV Callahan, ... Gastroenterology 159 (3), 1129-1131. e3, 2020 | 309 | 2020 |
| Combining Google Earth and GIS mapping technologies in a dengue surveillance system for developing countries AY Chang, ME Parrales, J Jimenez, ME Sobieszczyk, SM Hammer, ... International journal of health geographics 8, 1-11, 2009 | 276 | 2009 |
| Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies WB Williams, HX Liao, MA Moody, TB Kepler, SM Alam, F Gao, K Wiehe, ... Science 349 (6249), aab1253, 2015 | 226 | 2015 |
| Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial M Markowitz, I Frank, RM Grant, KH Mayer, R Elion, D Goldstein, C Fisher, ... The lancet HIV 4 (8), e331-e340, 2017 | 225 | 2017 |
| Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections ME Sobieszczyk, EY Furuya, CM Hay, P Pancholi, P Della-Latta, ... Journal of Antimicrobial Chemotherapy 54 (2), 566-569, 2004 | 208 | 2004 |
| Bacteremia and blood culture utilization during COVID-19 surge in New York City J Sepulveda, LF Westblade, S Whittier, MJ Satlin, WG Greendyke, ... Journal of clinical microbiology 58 (8), 10.1128/jcm. 00875-20, 2020 | 199 | 2020 |
| Characterization of bacterial and fungal infections in hospitalized patients with coronavirus disease 2019 and factors associated with health care-associated infections CJ Kubin, TH McConville, D Dietz, J Zucker, M May, B Nelson, E Istorico, ... Open forum infectious diseases 8 (6), ofab201, 2021 | 170 | 2021 |
| Clinical characteristics and outcomes in people living with human immunodeficiency virus hospitalized for coronavirus disease 2019 N Shalev, M Scherer, ED LaSota, P Antoniou, MT Yin, J Zucker, ... Clinical Infectious Diseases 71 (16), 2294-2297, 2020 | 167 | 2020 |
